AstraZeneca's Farxiga steps on FDA fast track toward CV outcomes nod

16th September 2019 Uncategorised 0

When SGLT2 med Farxiga scored a major cardiovascular outcomes win last month, AstraZeneca touted the trial results as a game changer for the market. Turns out the FDA likes those results, too—and it’s expediting a review of Farxiga’s CV label hopes.

More: AstraZeneca's Farxiga steps on FDA fast track toward CV outcomes nod
Source: fierce